Clinical trial
Prognostic Significance of the TREM-1 Pathway Activation in COVID-19
NCT04544891 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prognostic Significance of the TREM-1 Pathway Activation in COVID-19
- Lead sponsor
- Central Hospital, Nancy, France
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 1, 2020
- Completion date
- March 1, 2022
- Enrollment
- 830 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
covid19